Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Australia’s CSL Limited has sought to shed light on the promise of its pipeline at its annual R&D investor briefing. 3 November 2022
Biotechnology
Times are tough for cell medicine specialist Rubius Therapeutics, with the firm announcing plans to slash its workforce by 84%, part of a drastic effort to avoid bankruptcy. 3 November 2022
Biotechnology
Ireland-incorporated biotech Alkermes’ shares closed up 3.5% at $24.06 yesterday, as it pleased investors when it revealed that it is to explore separating its commercial-stage neuroscience business and development-stage oncology business. 3 November 2022
Biotechnology
Arcturus Therapeutics, a US messenger RNA (mRNA) company focused on the development of infectious disease vaccines, saw its shares rocket up nearly 24% to $22.63 yesterday on news of what could be an up to $4.5 billion deal relating to its technology. 3 November 2022
Pharmaceutical
Gianfranco Nazzi has stepped down effective November 2 from his role as chief executive of Spanish skincare specialist Almirall (ALM: MC) to pursue new professional opportunities. 3 November 2022
Biotechnology
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an evidence report on the comparative clinical effectiveness of hemophilia treatments. 2 November 2022
Biotechnology
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease. 2 November 2022
Pharmaceutical
Shares of Danish diabetes care giant Novo Nordisk were up 6.4% at 852.60 kroner by mid-afternoon today, after it released financial results, showing that sales increased by 26% in Danish kroner and by 16% at constant exchange rates (CER) to 128.9 billion kroner ($17.12 billion) in the first nine months of 2022. 2 November 2022
Pharmaceutical
Third quarter 2022 revenues of £7.8 billion ($9 billion) for GSK represent a significant outperform by most analysts’ lights - the consensus ahead of results day was £7.3 billion, according to data from the FT. 2 November 2022
Pharmaceutical
Rigel Pharmaceuticals’ share were up 3.4% at $0.75 yesterday, after it announced encouraging top-line efficacy and safety results from the FOCUS Phase III clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors. 2 November 2022
Biotechnology
A landmark approval in infectious diseases could be achieved by the end of the year, after New York pharma giant Pfizer reported fast progress in its respiratory syncytial virus (RSV) vaccine program. 2 November 2022
Biotechnology
Spain's AELIX Therapeutics, a spin-off of the HIVACAT vaccine research consortium, has published in Nature results from the AELIX-002 trial. 2 November 2022
Pharmaceutical
US healthcare giant Johnson & Johnson yesterday revealed it is making its largest acquisition in six years and potentially one of the biggest deals by a pharma this year. 2 November 2022
Biosimilars
Four years after it was established, Syna Therapeutics has just signed an exclusive license agreement with Indian drugmaker Intas Pharmaceuticals and its wholly-owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702 to treat pathologies in the field of hematology. 2 November 2022
Pharmaceutical
Continuing its extraordinary ascent, the world’s largest pharmaceutical firm, Pfizer, reported solid financial results in the third quarter, with revenues of $22.6 billion. 1 November 2022
Biotechnology
Switzerland-headquartered antibody-drug conjugate specialist ADC Therapeutics today announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17, 2022, and Peter Graham as chief legal officer, effective today. 1 November 2022
Pharmaceutical
US pharma major Eli Lilly saw its shares fall more than 4.7% to $344.91, after it released third-quarter 2022 financial results, along with a lowered full-year guidance. 1 November 2022
Pharmaceutical
The share of US pharma giant Pfizer’s erectile dysfunction drug Viagra (sildenafil) in the Russian market is steadily declining, due to the ever-growing competition from local generics and serious interruptions with supplies of the drug from Europe. 1 November 2022
Pharmaceutical
A new prefilled autoinjector pen for diabetics, Ogluo (glucagon) has been launched in Germany by Tetris Pharma, a subsidiary of British firm Arecor Therapeutics. 1 November 2022
Biotechnology
Adding to a string of recent research collaborations, Japanese drugmaker Ono Pharmaceutical has signed a drug discovery agreement for drugs in the immuno-oncology field with Swiss biotech Memo Therapeutics (MTx), an innovator in the field of antibody discovery and development. 1 November 2022
All news
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Generics
The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA). 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Pharmaceutical
UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month, the General Court of the European Union (General Court) has decided not to further extend the suspension of the European Commission (EC) decision to revoke the conditional marketing authorization (CMA) for Ocaliva (obeticholic acid) in Europe. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Pharmaceutical
According to a report from industry analyst DelveInsight, the market for Down syndrome treatments in the USA is now valued at almost $250 million. 27 November 2024
Pharmaceutical
The European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y, UK pharma major GSK announced today. 27 November 2024
Pharmaceutical
The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA. 27 November 2024
Pharmaceutical
Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Pharmaceutical
The Biden administration has proposed a new rule that could significantly expand Medicare and Medicaid coverage for obesity medications, potentially benefiting millions of Americans. 27 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Pharmaceutical
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze